Swiss Luxury Stock News

SWX:SOON
SWX:SOONMedical Equipment

Sonova Holding (SWX:SOON) Is Up 9.8% After Record Dividend And Strong Normalized EBITA Growth - What's Changed

Sonova Holding AG has released its full-year results for the period ended March 31, 2026, reporting sales of CHF 3,605.9 million, net income of CHF 430.6 million, and announcing an annual dividend of CHF 4.70 per share payable on June 23, 2026. Despite lower reported net income year-on-year, the company achieved 5.9% sales growth and a 17.3% increase in normalized EBITA in local currencies, primarily driven by its Hearing Instruments segment and supported by business reshaping and the...
SWX:CMBN
SWX:CMBNConsumer Finance

European Dividend Stocks To Consider For Income

As European markets navigate the challenges of geopolitical tensions and inflationary pressures, investors continue to seek stability and growth through dividend stocks. In such a climate, selecting stocks with robust earnings growth and consistent dividend payouts can be an effective strategy for those looking to generate income while potentially mitigating volatility.
SWX:AMS
SWX:AMSSemiconductor

A Look At Ams-OSRAM (SWX:AMS) Valuation After Q1 2026 Earnings And Softer Revenue Guidance

ams-OSRAM (SWX:AMS) drew fresh attention after reporting first quarter 2026 results that showed lower sales and a wider net loss, alongside new guidance indicating slightly softer full-year revenue due to divestments and currency effects. See our latest analysis for ams-OSRAM. The Q1 results and softer full year guidance came after a sharp rebound in the stock, with a 30 day share price return of 50.80% and a 90 day share price return of 119.51%. However, the 3 year total shareholder return...
SWX:NOVN
SWX:NOVNPharmaceuticals

Assessing Novartis (SWX:NOVN) Valuation After Promising Pluvicto Prostate Cancer Data

Novartis (SWX:NOVN) is back in focus after new clinical data showed its radioligand therapy Pluvicto, when added to standard treatment, cut the risk of PSA progression by 58% in a specific prostate cancer setting. See our latest analysis for Novartis. Alongside the Pluvicto data and a series of US manufacturing and research expansions, Novartis has seen firm investor interest, with the share price at CHF117.2 and an 8.02% year to date share price return, while the 1 year total shareholder...
SWX:SCMN
SWX:SCMNTelecom

Is It Too Late To Consider Swisscom (SWX:SCMN) After A 27% One-Year Rally?

Investors may be asking whether Swisscom at CHF676.0 is offering fair value right now, or if the recent momentum has already priced in the opportunity. The stock has returned 1.0% over the past week, 3.9% over the past month, 16.8% year to date, and 27.2% over the last year, which naturally raises questions about how much of its potential is already reflected in the price. Recent attention on Swisscom has focused on its role as a major Swiss telecom operator and how investors view its...
SWX:ADEN
SWX:ADENProfessional Services

Assessing Adecco Group (SWX:ADEN) Valuation After Q1 2026 Earnings And AI Productivity Push

Q1 earnings spark fresh look at Adecco Group stock Adecco Group (SWX:ADEN) just released Q1 2026 results, with organic revenue growth, higher net income and EBITA, and market share gains in the Americas and APAC putting the stock back in focus. See our latest analysis for Adecco Group. Despite the Q1 2026 earnings lift, the share price has fallen 36.36% year to date, contributing to a 33.17% decline in 1 year total shareholder return and signalling fading momentum despite improving...
SWX:NOVN
SWX:NOVNPharmaceuticals

Is Novartis’ US Radioligand Manufacturing Buildout (SWX:NOVN) Altering Its Investment Case?

In early May 2026, Novartis broke ground on a new 46,000 sq. ft radioligand therapy manufacturing facility in Denton, Texas, part of its US$23.00 billion US manufacturing and research expansion and its fifth radioligand therapy site nationwide. This build-out of a coast-to-coast radioligand therapy network highlights how Novartis is tying manufacturing proximity and reliability directly to complex cancer treatment delivery for US patients. We will now explore how this expanded US radioligand...
SWX:LAND
SWX:LANDElectronic

Landis+Gyr Group (SWX:LAND) Valuation Check After Annual Loss And Weak Long Term Returns

Landis+Gyr Group (SWX:LAND) has recently drawn attention after its latest financial data showed annual revenue of $1,625.8m and a net loss of $136.1m, prompting investors to reassess the smart metering specialist. See our latest analysis for Landis+Gyr Group. At a share price of CHF47.85, Landis+Gyr Group has seen short term share price momentum pick up, with a 7 day share price return of 6.93%. However, longer term total shareholder returns over 3 and 5 years remain weak and suggest...
SWX:TEMN
SWX:TEMNSoftware

Assessing Temenos (SWX:TEMN) Valuation After New Banking Deals And AI Product Launches

Temenos (SWX:TEMN) is back in focus after a cluster of fresh contracts and product launches, including new core banking deals with Habib Bank Limited and Reliance Bank, as well as extended collaborations with First Abu Dhabi Bank and Questrade Financial Group. See our latest analysis for Temenos. The recent stream of banking deals and AI product launches comes against a mixed backdrop. The share price stands at CHF71.45, with a 90 day share price return of 11.29%, but a year to date share...
SWX:ABBN
SWX:ABBNElectrical

ABB Hyper-Efficiency Hazardous Motor Puts Valuation Expectations To The Test

ABB (SWX:ABBN) has launched what it describes as the world's first IE6 Hyper-Efficiency motor for hazardous areas. The new motor uses rare earth and magnet free SynRM technology and is certified for use in hazardous environments. The product has received both ATEX and IECEx certifications, targeting sectors such as chemicals, oil & gas, and food manufacturing. ABB operates across electrification and automation, supplying equipment and systems that support industrial customers and critical...
SWX:ADEN
SWX:ADENProfessional Services

Adecco Group (SWX:ADEN) Margin Stagnation Challenges Bullish Profit Expansion Narrative

Adecco Group (SWX:ADEN) opened 2026 with Q1 revenue of €5.7b and basic EPS of €0.41, setting a clear benchmark for how the year is starting after a steady run of quarterly results. The company has seen revenue move from €5.6b in Q1 2025 to €5.7b in Q1 2026, while basic EPS over that same period went from €0.36 to €0.41. Trailing twelve month EPS of €1.81 provides a broader earnings backdrop. With net income of €69m in the quarter and a net profit margin of 1.3%, the story now is how...
SWX:SUNN
SWX:SUNNTelecom

Sunrise Communications Q1 Loss Of CHF 40 Million Keeps Profitability Narrative Under Pressure

Sunrise Communications (SWX:SUNN) opened 2026 with Q1 revenue of CHF 722.8 million and a loss per share of CHF 0.55, as net income excluding extra items came in at a loss of CHF 40.3 million. Over the past year, revenue has moved in a relatively tight range between CHF 722.1 million and CHF 788.8 million per quarter, while quarterly EPS has fluctuated between a loss of CHF 0.02 and a loss of CHF 2.00. This puts the latest trailing twelve-month EPS at a loss of CHF 2.08. For investors, the key...
SWX:HLEE
SWX:HLEEEntertainment

Highlight Event And Entertainment (SWX:HLEE) Widening Loss Challenges Value Thesis Despite Low P/S

Highlight Event and Entertainment (SWX:HLEE) has posted its FY 2025 results, reporting first half revenue of CHF194.9 million and a loss per share of CHF1.20. On a trailing twelve month basis, revenue stands at CHF544.4 million with a loss per share of CHF10.65, reflecting ongoing profitability pressures. Over recent periods, revenue has moved between CHF235.5 million and CHF310.3 million per half year, while basic EPS has ranged from a loss of CHF0.85 to a loss of CHF1.20. This highlights...
SWX:ZUBN
SWX:ZUBNReal Estate

Züblin Immobilien Holding (SWX:ZUBN) One Off Gain Clouds Earnings Narratives

Züblin Immobilien Holding (SWX:ZUBN) has reported its FY 2026 results with first half revenue of CHF 4.95 million and basic EPS of CHF 1.31, while trailing 12 month figures show revenue of CHF 9.84 million and basic EPS of CHF 2.27, both shaped by a CHF 3.1 million one off gain in the period. Over recent periods, revenue has moved from CHF 4.37 million in the first half of FY 2025 to CHF 4.80 million in the second half and then CHF 4.95 million in the first half of FY 2026. EPS shifted from...
SWX:ADEN
SWX:ADENProfessional Services

Akkodis AI Recognition Puts Focus On Adecco Group Valuation Gap

Akkodis, a subsidiary of Adecco Group (SWX:ADEN), has been recognized as an Enterprise Innovator for its agentic AI capabilities. The recognition highlights Akkodis' progress in practical AI deployment and Services-as-Software transformation across enterprise clients. The assessment emphasizes strengths in scalable AI execution and data governance, pointing to operational impact beyond financial metrics. Adecco Group, through Akkodis, is leaning into AI driven services at a time when large...
SWX:ROP
SWX:ROPPharmaceuticals

Roche Alzheimer’s Blood Test Approval Adds Weight To Diagnostics Story

Roche Holding received CE Mark approval for its Elecsys pTau217 blood test for Alzheimer's disease in Europe. The assay is designed to detect amyloid pathology through a minimally invasive blood draw, supporting faster assessment in primary and secondary care. The approval adds to Roche's diagnostics portfolio in neurodegenerative disease and may influence how clinicians approach early Alzheimer's evaluation. For investors tracking SWX:ROP, the CE Mark arrives with the stock trading at...
SWX:SCMN
SWX:SCMNTelecom

Swisscom (SWX:SCMN) Valuation In Focus After Recent Share Price Move And Conflicting Fair Value Signals

Swisscom shares in focus after recent price move Swisscom (SWX:SCMN) has come into focus for investors after a recent share price move, with the stock last closing at CHF 678. This has drawn attention to its recent performance and valuation signals. See our latest analysis for Swisscom. Beyond the latest move to CHF 678, Swisscom’s recent momentum has been relatively steady, with a 30 day share price return of 2.57%, while the 1 year total shareholder return of 31.29% highlights the longer...
SWX:UBSG
SWX:UBSGCapital Markets

A Look At UBS Group (SWX:UBSG) Valuation After Recent Share Price Momentum And Mixed Analyst Targets

Recent performance snapshot UBS Group (SWX:UBSG) has drawn investor attention after a recent move in the share price, with the stock last closing at CHF 36.22. That puts its market value around CHF 106b. Over the past month, the stock has returned 9.6%, and over the past 3 months it has returned 12.4%. The 1 year total return stands at 35.0%, with a 3 year total return a little over 12x and a 5 year total return almost 20x. See our latest analysis for UBS Group. The recent 1 day share price...